EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen

Sara Nyback, Inger Sundström Poromaa, Henrik Lindman, Angelica Lindén Hirschberg, Helena Kopp Kallner, Anna Wikman, Theodora Kunovac Kallak

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116261 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Sara Nyback und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden. Hauptthemen laut MEDLINE: Tamoxifen, Postmenopause, Vagina, Vaginal Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Percy Falks Foundation for Research into Prostate Cancer and Breast Cancer, Percy Falk Foundation, Magnus Bergvalls Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a great need for non-estrogenic treatment of vulvovaginal atrophy (VVA) symptoms affecting sexual function and quality of life. Women with breast cancer on anti-estrogenic therapy are particularly vulnerable and in need of help. The primary aim of this proof-of-concept trial was to evaluate the efficacy of vaginal tamoxifen in reducing the most troublesome VVA symptom. METHODS: In this randomized, double blind, placebo-controlled study, 115 postmenopausal women, with or without breast cancer, were randomized to 20 mg vaginal tamoxifen once weekly or placebo (1:1). Follow-up after one and three-months of treatment, included self-reported VVA symptoms on the Endocrine Symptom Subscale of FACT-B, and gynecologic exams for VVA score and measurement of vaginal pH and endometrial thickness. FINDINGS: After three months, 37 (68.6 %) of women on vaginal tamoxifen reported their most troublesome VVA symptom to be mild or not present at all, whereas corresponding number in the placebo group was 5 (9.1 %), p < 0.001. Expressed as odds, women on vaginal tamoxifen were more likely to report no or minor symptoms after three-months, OR 21.76 (95 % CI 7.36 - 64.3). The improvement in self-reported outcomes was accompanied by improvements in VVA scores and vaginal pH, p < 0.001. INTERPRETATION: This study has demonstrated that more than two-thirds of the women on vaginal tamoxifen improved in their most troublesome VVA symptom. This is likely due to a tamoxifen-induced estrogen agonistic effects in vagina in a low-estrogen environment. While findings are promising, further studies on improved vaginal administration and endometrial safety concerns are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TamoxifenPostmenopauseVaginaVaginal DiseasesBreast NeoplasmsHumansFemaleAtrophyAdministration, IntravaginalDouble-Blind MethodMiddle AgedTreatment OutcomeAgedQuality of LifeProof of Concept Study

Stichwörter der Autor:innen

Aromatase inhibitorsBreast cancerPain during sexVaginal tamoxifenVulvovaginal atrophy

Substanzen

Tamoxifen

Autor:innen und Institutionen

  • Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden.
  • Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, Sweden.
  • Department of Women's and Children's Health, Uppsala university, Uppsala, Sweden. Electronic address: theodora.kunovac_kallak@uu.se.

Förderung

  • Percy Falks Foundation for Research into Prostate Cancer and Breast Cancer
  • Percy Falk Foundation
  • Magnus Bergvalls Stiftelse
  • Cancerfonden
  • Swedish Cancer Foundation

Zitieren

APA

Nyback, S., Poromaa, I. S., Lindman, H., Hirschberg, A. L., Kallner, H. K., Wikman, A., & Kallak, T. K. (2026). Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116261

Vancouver

Nyback S, Poromaa IS, Lindman H, Hirschberg AL, Kallner HK, Wikman A, et al. Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116261

BibTeX
@article{Nyback2026,
  author = {Nyback, Sara and Poromaa, Inger Sundström and Lindman, Henrik and Hirschberg, Angelica Lindén and Kallner, Helena Kopp and Wikman, Anna and Kallak, Theodora Kunovac},
  title = {Vaginal tamoxifen – A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116261}
}
Kostenlos starten →